Wall Street Zen Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"

Key Points

• Wall Street Zen upgraded Precigen to “Strong Buy,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $14.50. Ratings are mixed, ranging from Strong Buy to Sell.
• Precigen reported $54.98 million in quarterly revenue, far above the $27.98 million consensus estimate, and EPS of $0.05 versus expectations for a $0.01 loss. Revenue increased more than 6,300% year over year.
• Institutional investors increased their exposure, including BlackRock’s new position valued at roughly $97.7 million, but insiders sold nearly 989,000 shares worth $5.5 million over the past 90 days.

Precigen (NASDAQ:PGEN - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "strong-buy" rating in a research report issued on Saturday.

Several other research analysts have also recently issued reports on PGEN. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precigen in a report on Friday, July 17th. Citigroup reissued an "outperform" rating on shares of Precigen in a research note on Thursday, May 14th. HC Wainwright lifted their target price on Precigen from $14.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday. Zacks Research raised Precigen from a "hold" rating to a "strong-buy" rating in a research report on Wednesday. Finally, Citizens Jmp upped their target price on Precigen from $9.00 to $11.00 and gave the company a "market outperform" rating in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $14.50.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $7.23 on Friday. Precigen has a twelve month low of $1.70 and a twelve month high of $7.26. The company has a current ratio of 4.58, a quick ratio of 4.12 and a debt-to-equity ratio of 2.15. The firm has a 50-day moving average of $5.23 and a two-hundred day moving average of $4.50. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of -6.95 and a beta of 1.02.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The company had revenue of $54.98 million for the quarter, compared to analysts' expectations of $27.98 million. The company's quarterly revenue was up 6322.7% compared to the same quarter last year. As a group, analysts expect that Precigen will post 0.05 earnings per share for the current fiscal year.

Insider Activity at Precigen

In other Precigen news, COO Rutul R. Shah sold 32,739 shares of Precigen stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $6.86, for a total value of $224,589.54. Following the completion of the sale, the chief operating officer directly owned 465,012 shares in the company, valued at $3,189,982.32. The trade was a 6.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Sabzevari sold 346,836 shares of the company's stock in a transaction on Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the completion of the sale, the chief executive officer owned 3,768,872 shares of the company's stock, valued at $22,198,656.08. This represents a 8.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 989,239 shares of company stock worth $5,472,960. Corporate insiders own 41.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PGEN. BlackRock Inc. acquired a new position in shares of Precigen during the second quarter valued at about $97,737,000. State Street Corp boosted its stake in Precigen by 141.1% during the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company's stock worth $45,248,000 after buying an additional 6,335,033 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Precigen by 15.9% in the 4th quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company's stock valued at $18,653,000 after buying an additional 613,340 shares in the last quarter. Occam Crest Management LP lifted its holdings in shares of Precigen by 29.6% during the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company's stock worth $14,637,000 after acquiring an additional 799,339 shares during the period. Finally, SymBiosis Capital Partners LLC bought a new position in shares of Precigen during the 4th quarter worth about $12,540,000. Institutional investors own 33.51% of the company's stock.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong earnings and commercial momentum: Precigen reported second-quarter 2026 revenue of approximately $55 million, far exceeding analyst expectations, and earnings of $0.05 per share versus the expected $0.01 loss. Revenue was driven largely by PAPZIMEOS, whose sales reportedly doubled sequentially to $53.1 million. The company also achieved quarterly profitability, supporting the view that its commercial business is scaling rapidly. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: More favorable analyst outlook: HC Wainwright maintained a Buy rating and an $18 price target while raising its Q3 2026 EPS forecast to $0.05 from $0.01 and its full-year 2026 forecast to $0.14 from $0.02. The firm also lifted its FY2027 estimate to $0.44 from $0.34, reflecting expectations for continued profitability and growth. HC Wainwright Precigen Estimates
• Positive Sentiment: Additional bullish ratings: Zacks Research upgraded Precigen from “Hold” to “Strong Buy.” Separately, an investment analysis cited PAPZIMEOS’ FDA approval for recurrent respiratory papillomatosis, seven years of U.S. market exclusivity, possible European approval, and advancement of the PRGN-2009 program as potential drivers of future revenue. Zacks Research
• Neutral Sentiment: HC Wainwright’s projections imply a sharp earnings ramp, reaching $0.71 EPS in FY2028 and $1.49 EPS in FY2030. However, the firm made a small reduction to its FY2028 estimate, from $0.72 to $0.71, indicating that longer-term forecasts remain subject to execution risk.

About Precigen

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source